PMV PHARMACEUTICALS, INC. Financing Cash Flow
PMV PHARMACEUTICALS, INC. (PMVP) reported Financing Cash Flow of $143.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $143.00K, a 38.83% increase year-over-year.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $392.00K, a 127.91% increase year-over-year.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $505.00K, a 61.34% increase from fiscal 2024.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $313.00K, a 99.12% decline from fiscal 2023.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $35.58M, a 3613.67% increase from fiscal 2022.
- PMV PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $958.00K, a 52.62% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $143.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $143.00K 10-Q · filed 2026-08-14 | $535.00K derived: sum of 3 quarters · filed 2026-08-14 | $535.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $392.00K derived: sum of 2 quarters · filed 2026-05-12 | $392.00K derived: sum of 3 quarters · filed 2026-05-12 | $495.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $392.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $392.00K derived: sum of 2 quarters · filed 2026-03-06 | $495.00K derived: sum of 3 quarters · filed 2026-08-14 | $505.00K 10-K · filed 2026-03-06 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $103.00K derived: sum of 2 quarters · filed 2026-08-14 | $113.00K 10-Q · filed 2025-11-12 | $285.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $113.00K 10-Q · filed 2026-08-14 | $285.00K derived: sum of 3 quarters · filed 2026-08-14 | $285.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $10.00K 10-Q · filed 2026-05-12 | $182.00K derived: sum of 2 quarters · filed 2026-05-12 | $182.00K derived: sum of 3 quarters · filed 2026-05-12 | $323.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $172.00K derived: sum of 2 quarters · filed 2026-03-06 | $313.00K derived: sum of 3 quarters · filed 2026-03-06 | $313.00K 10-K · filed 2026-03-06 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $141.00K derived: sum of 2 quarters · filed 2025-11-12 | $141.00K 10-Q · filed 2025-11-12 | $429.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $141.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $141.00K 10-Q · filed 2025-08-07 | $429.00K derived: sum of 3 quarters · filed 2026-03-06 | $33.58M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | $288.00K derived: sum of 2 quarters · filed 2026-03-06 | $33.43M derived: sum of 3 quarters · filed 2026-03-06 | $35.56M derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | $288.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $33.43M derived: sum of 2 quarters · filed 2026-03-06 | $35.56M derived: sum of 3 quarters · filed 2026-03-06 | $35.58M 10-K · filed 2026-03-06 |
| 2023-09-30 | $33.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $35.28M derived: sum of 2 quarters · filed 2024-11-07 | $35.29M 10-Q · filed 2024-11-07 | $35.84M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.14M 10-Q · filed 2024-08-08 | $2.69M derived: sum of 3 quarters · filed 2025-03-03 | $2.70M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $12.00K 10-Q · filed 2024-05-09 | $560.00K derived: sum of 2 quarters · filed 2025-03-03 | $566.00K derived: sum of 3 quarters · filed 2025-03-03 | $842.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $548.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $554.00K derived: sum of 2 quarters · filed 2025-03-03 | $830.00K derived: sum of 3 quarters · filed 2025-03-03 | $958.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $282.00K derived: sum of 2 quarters · filed 2023-11-09 | $410.00K 10-Q · filed 2023-11-09 | $705.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $276.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $404.00K 10-Q · filed 2023-08-09 | $699.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.01M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $128.00K 10-Q · filed 2023-05-10 | $423.00K derived: sum of 2 quarters · filed 2024-02-29 | $732.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.99M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $604.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.86M derived: sum of 3 quarters · filed 2024-02-29 | $2.02M 10-K · filed 2024-02-29 |
| 2021-09-30 | $309.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.56M derived: sum of 2 quarters · filed 2022-11-08 | $1.73M 10-Q · filed 2022-11-08 | $368.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.42M 10-Q · filed 2022-08-09 | $59.00K derived: sum of 3 quarters · filed 2023-03-01 | $294.51M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $162.00K 10-Q · filed 2022-05-10 | -$1.20M derived: sum of 2 quarters · filed 2023-03-01 | $293.26M derived: sum of 3 quarters · filed 2023-03-01 | |
| 2020-12-31 | -$1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $293.10M derived: sum of 2 quarters · filed 2023-03-01 | $292.97M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $294.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $294.33M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$124.00K 10-Q · filed 2021-08-13 | |||
| 2019-12-31 | $61.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $61.80M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $100.00K 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |